Fineline Cube

Follow:
14778 Articles
Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024
Policy / Regulatory

Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024

Alphamab Oncology and CSPC Pharma's KN026 Phase III Trial for Breast Cancer Gets NMPA Approval
CompanyDrug

Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval

Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement
CompanyDeals

Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
Company

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress

Shanghai Junshi Biosciences' Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma
CompanyDrug

Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma

Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D
Company

Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D

Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA
CompanyDrug

Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA

Innovec Pharma's IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China's CDE
CompanyDrug

Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE

Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment
CompanyDrug

Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment

Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication
CompanyDrug

Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer
CompanyDrug

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer

Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor
CompanyDeals

Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor